Eight drimane sesquiterpenoids including (-)-drimenol and (+)-albicanol were synthesized 26 from (+)-sclareolide and evaluated for their antifungal activities. Three compounds, (-)-drimenol, 27 (+)-albicanol, and (1R,2R,4aS,8aS)-2-hydroxy-2,5,5,8a-tetramethyl-decahydronaphthalene-1-28 carbaldehyde (4) showed strong activity against C. albicans. (-)-Drimenol, the strongest inhibitor 29 of the three, (at concentrations of 8 -64 g/ml, causing 100% death of fungi), acts not only against 30 C. albicans as a fungicidal manner, but also inhibits other fungi such as Aspergillus, Cryptococcus, 31 Pneumocystis, Blastomyces, Fusarium, Rhizopus, Saksenaea and FLU resistant strains of C. 32 albicans, C. glabrata, C. krusei, C. parapsilosis and C. auris. These observations suggest drimenol 33 is a broad-spectrum antifungal agent. At high concentration (100 μg/ml), drimenol caused a 34 rupture of the fungal cell wall/membrane. In a nematode model of C. albicans infection, drimenol 35 rescued the worms from C. albicans-mediated death, indicating drimenol is tolerable and bioactive 36 in a metazoan. Genome-wide fitness profiling assays of both S. cerevisiae (nonessential 37 homozygous and essential heterozygous) and C. albicans (Tn-insertion mutants) collections 38 revealed putative genes and pathways affected by drimenol. Using a C. albicans mutants spot 39 assay, the Crk1 kinase associated gene products, Ret2, Cdc37, and novel putative targets 40 orf19.759, orf19.1672, and orf19.4382 were revealed to be the potential targets of drimenol. 41 Further, computational modeling results suggest possible modification of the structure of drimenol 42 including the A ring for improving antifungal activity. 43 44 45 46 47 48 Life-threatening fungal infections are an important cause of morbidity and mortality, 49 particularly for patients with immune deficiency and those who are undergoing chemotherapeutic 50 treatments. Some of the leading invasive fungal pathogens include Candida sp., Aspergillus sp. 51 and Cryptococcus sp. Currently, the antifungal therapeutic options are limited, especially when 52 compared to available antibacterial agents (1-4). Among the five classes of antifungals, azoles, 53 echiocandins, polyenes, allylamines, and pyrimidine derivatives, only three are used clinically; 54 azoles, echiocandins, and polyenes. Azole drugs, such as fluconazole (FLU), inhibit ergosterol 55 synthesis through inhibition of lanosterol 14--demethylase, impairing formation of the fungal 56 cell wall. Echocandins, such as caspofungin (CAS), block 1,3--glucan synthase and lead to 57 depletion of glucan in fungal cell wall. Polyenes, including amphotericin B (AMB), bind to 58 ergosterol in fungal cell membrane and change the cell membrane transition temperature, resulting 59 in leakage of ions and small organic molecules, and eventual cell death. Allylamines, such as 60 amorolfin, affect ergosterol synthesis by inhibition of squalene epoxidase. Pyrimidines, such as 61 flucytosine (or 5-fluorocytosine), block nucleic acid synthesis, leading to the inhibition of protein 62 synthesis (5, 6). No new antifungal agents have been approved by Food and Drug Administration 63 since 2006 (2) and the latest antimycotic agents, echinocandins, were developed over 30 years ago 64 (7, 8).. Thus, new broad-spectrum antifungal agents are sorely needed to overcome the increasing 65 emergence of antifungal drug resistance. 66
INTRODUCTION
invasion of cells, immune evasion, and biofilm formation. Furthermore, the ability to switch 71 between forms is also essential for pathogenicity. Traditional antimycotics have many drawbacks, 72 including toxicity to human cells, a limited range of cellular targets, the development of antifungal 73 resistance (9-12), and the failure to successfully control pathogenesis. To develop new antifungal 74 agents based on drimane sesquiterpenes, we have investigated synthetic drimane terpenes, (-)-75 drimenol (1) and (+)-albicanol (2), along with six analogs, 3 -8 ( Fig. 1) , for their antifungal 76 activities and identified (-)-1 as a potent broad-spectrum fungicidal agent. Moreover, we 77 determined their mechanism of action through forward genetic screening of mutant libraries of C. 78 albicans and baker's yeast and found that (-)-1 affects the fungal activities of protein secretion, 79 vacuolar biogenesis, chromation remodeling and cyclin dependent protein kinases (CDK) activity. 80
81

RESULTS 82
Several drimane sesquiterpenoids were synthesized in our laboratory during the total synthesis of 83 (+)-chloropuupehenone, a natural product from marine sponges (13). Based on the 84 antimycobacterial activity of sesquiterpene natural product, cinnamodial, isolated from the 85 liverwort plant, Warburgia salutaris (14), we anticipated that drimane sesquiterpenes and closely 86 related compounds (15) could be effective antimycotics for C. albicans. Five representative 87 drimane terpenes, 1 -5, along with their derivatives, 6 -8 ( Fig. 1) , were screened for their ability 88 to inhibit C. albicans growth. It was assumed that additional hydroxyl group(s) or oxygen atoms 89 in the molecule enhances water solubility and may improve bioactivity (16). Compounds 1 -5 were prepared by following previously reported methods (13). Molecule 97 6 was prepared from a mono-acetylation of 5 with acetic anhydride and pyridine in 98 dichloromethane (Scheme 1). Molecule 7 was made by a sequence of three reactions: (i) silylation 99 of the primary alcohol with t-butyldimethylsilyl chloride and imidazole in dichloromethane; (ii) 100 acetylation of the tertiary alcohol with acetyl chloride and pyridine; and (iii) removal of the silyl 101 ether group with tetra-n-butylammonium fluoride in THF. Compound 8 was produced from the 102 treatment of triol 3 with 2,2-dimethoxylpropane and a catalytic amount of p-toluenesulfonic acid 103 in toluene. The experimental procedures were described in Materials and Methods section. 104 Scheme 1. Synthesis of drimane sesquiterpenoids 3 -8. 106
Examinataion of the antifungal activities of these molecules along with the mechanistic 107 study of the most active molecule may allow future improvement in bioactivity and reduction in 108 toxicity. We used C. albicans strain SC5314 for our initial screening of antifungal activities of 109 drimane sesquiterpenoids 1 -8. The compounds were solubilized in dimethyl sulfoxide (DMSO), 110 10 mg/ml, as stock solutions and stored at -20 o C. Prior to assays, stock solutions of compounds 111 were diluted to 200 -12.5 µg/ml in the growth media for yeast antifungal assays using the Clinical 112 and Laboratory Standards Institute (CLSI) M38-A2 method (17). Fortuitously, we found (-)-113 drimenol (1) and (+)-albicanol (2) along with compound 4, inhibit C. albicans SC5314 growth 114 ( Representative microscopic images (Leica, inverted microscope) taken at 200X magnification 145 from 1 with cells exposed 50 μg/ml (MIC), except T. equinum which was exposed to 15 μg/ml at 146 Results summarized in Fig. 2 show that 1 has broad-spectrum fungicidal activity against various 152 fungi including FLU resistant C. alibcans and Cryptococcus sp albeit, at a higher (50 μg/ml) MIC 153 concentration. However, for a dermatophyte fungus, the MIC value was lower, 15 μg/ml. When 154 compared to DMSO controls, fungi exposed to 1 showed absence of fungal growth. At higher 155 concentration of 1 (100 μg/ml), C. albicans yeast cells lysed and released their cellular contents 156 ( Fig. 3, arrow) . Consistent with this observation, 1 inhibited the germination of A. nidulans spores 157 and appeared to cause swelling of germinating spores ( Fig. 3 Next, we determined the viability of fungal cells that were exposed to 1. Cells exposed to 181 50 μg/ml (MIC) for 24 h or at 100 μg/ml for 48h were used. To determine the viability of treated 182 fungal cells, small volumes (1 -5 μg/ml) of mixed cell suspensions were removed from wells and 183 spotted on YPD agar medium. The agar plates were incubated at 30 o C for 24 h -72 h and the 184 growth of fungi were recorded. Growth of yeasts occur in 24 h and filamentous fungi in 48 -72 h 185 for control (without 1) but not for those treated with 1 suggesting that it acts as a fungicidal 186 compound (data not shown). 187 188 Drimenol acts better than fluconazole against Candida auris growth 189 C. auris is an emerging multidrug resistant fungal pathogen that is known to cause nosocomial 190 infections with 'superbug"-like traits (18). C. auris was first discovered in 2009 in Southeast Asia 191 and now it is present in 33 countries across 6 continents. Since this fungus is resistant to all 192 antifungals and is invasive, the mortality rate is high (19) . Recently, CDC has issued a clinical 193 health emergency warning about this fungus. Since 1 showed a broad-spectrum fungicidal activity, 194 we determined its effect against C. auris growth using a bioscreen-C growth monitoring system. worms are alive as judged by their movements and the lack of fungal growth. 227
Mechanism of drimenol (1) antifungal activity 229
To understand the compound's mechanisms of action (MOA), researchers have used pooled library 230 of genome-wide barcoded mutant collections of Saccharomyces cerevisiae or C. albicans for drug-231 induced sensitivity assay or the haploinsufficiency (HIP) assay (21-23). For example, if 1 can 232 inactivate partially or completely its protein target in the heterozygous mutant pool, the resulting 233 growth defect of that mutant(s) can be measured quantitatively by sequencing the tagged unique 234 barcodes. This approach will help narrowing down the putative target(s). Similarly, a 235 homozygous nonessential mutant library can be used as a complementary approach to the 236 heterozygous essential mutant collection to verify the target pathway/genes of compounds. In this 237 case, if the homozygous mutant of a gene is sensitive to the compound, then that gene may not be 238 the drug target (21) as the homozygous mutant lacks the gene product. This imples that the 239 compound may exert its effect via drug-induced synthetic lethality. Thus, by combining data from 240 both heterozygote and homozygote screens one may determine the compound's MOA. 241
242
In this study, we used S. cerevisiae barcoded homozygous nonessential and heterozygous essential, 243 and C. albicans barcoded heterozygous Tn mutant (23) libraries. Briefly, IC-50 of 1 for C. 244 albicans and S. cerevisiae was determined in yeast growth (YPD) condition ( Fig. 6) . Based on 245 this assay results, IC-50 of 25 μg/ml for C. albicans and 15 μg/ml for S. cerevisiae was calculated 246 for 1. Two different sub-MIC concentrations of 1 were selected for determining the mechanism 247 of action against mutant libraries. albicans and ~15 μg/ml for S. cerevisiae were calculated for 1. Albicanol (2) showed weaker 254 activity against both fungi and was not considered for further analysis. 255 256 Next, pooled S. cerevisiae and C. albicans mutant collections were grown separately in the 257 presence or absence of compounds (with DMSO) for 20-generations, barcodes from genomic DNA 258 were amplified and relative strain abundance were quantified based on TAG microarray signals. 259
The log 2 ratio of tag signals between DMSO control and 1 exposed samples were presented in 260 scatter plots as the "fitness defect" (Figs. 7A & B) . Mutants that were depleted from the growth 261 pool due to 1 are indicated by circles. Mutants that were highly susceptible to 1 are shown with 262 high log ratio (e.g. SEC66 in Fig. 7A ) (highly depleted in the pool) and considered putative targets. 263 Lists of S. cerevisiae and C. albicans mutants that are highly sensitive to 1 were given in 264 Supplementary Tables 1 and 2 Fig. 7B ) gene product is involved in inosine 5'-monophosphate 5'-287 nucleotidase activity in C. albicans (Candida Genome Database). This gene product is 288 uncharacterized and it is present only in fungi and not in human or murine, suggesting that Isn1p 289 a suitable antifungal drug target. IFG3 is a putative D-amino acid oxidase, which is 290 uncharacterized, and CRK1 is a protein kinase of the Cdc2 subfamily involved in hyphal 291 development and virulence in C. albicans (24). The CRK1 ortholog in S. cerevisiae is SGV1, 292 which is a part of BUR2 kinase complex and plays a major role in transcriptional regulation. 293
294
Yeasts spot assay to validate drimenol (1) mechanism of action 295
Based on the forward genetic library screening assay results ( Fig. 7) and their functions inferred 296 from the available literature, we selected few heterozygous mutants of C. albicans that had high 297 to medium positive log 2 ratio (hypersensitive, CRK1 and its putative interacting partners proteins 298 Crk1 kinase, which are defective in growth on agar medium containing 1 (Fig. 8) . Molecule 1 330 induced hypersensitivity of these mutants, which represent candidate targets. The orf19.759 331 (SEC21 ortholog of S. cerevisiae) is uncharacterized in C. albicans. Sec21 involves in transport 332 from endoplasmic reticulum (ER) to Golgi vsicle-mediated transport (anterograde), Golgi to ER 333 (retrograde) and COPI vesicle coat, and endosome localization (27). RET2 is also uncharacterized 334 in C. albicans and the ortholog is a subunit of the coatomer complex (COPI), which coats Golgi-335 derived transport vesicles, involves in retrograde transport between Golgi and ER, and interacts 336 with Crk1 kinase in the two-hybrid system (28). Crk1 is known to play a role in regulating 337 trafficking and secretion of effectors by interacting with the early endosome during Ustilago 338 maydis (corn smut fungus) infection in corn plants (29, 30) . 339 340 Since Crk1 kinase may interact with multiple targets (Ret2, orf19.759, orf19.1672 and orf19.4382) 341 and because Crk1 represents an important antifungal drug target (24), we performed computational 342 molecular docking of 1 with Cryptosporidium parvum Crk1 crystal structure (2QKR-A) (31) using 343 AutoDock Vina software (32). Results showed in Fig. 9 , suggest that 1 can interact with the N-344 terminal catalytic domain of C. albicans Crk1 (which has 61% similarity and 40% identical to the 345 C. parvum Crk1). Particularly, noteworthy from our computational docking studies is that 1 has 346 close interactions with Gly 31, Val 37, Gln 148, Leu 151, and Phe 98 amino acid residues. The 347 docked structure shows that an available open space in Crk1 for incorporation of an additional 348 function group onto the cyclohexane A ring of 1 (Fig. 1) , signifying a possible modification of 1 349 for future improvement of biological activity. Thus, this CDK member may comprise the target 350 of 1 and it is notable that this conserved gene is present in many of the tested pathogenic fungi 351 (Table 2) In our search for novel antifungal small molecules from our available synthetic terpenoids, we 401 have identified two compounds, (-)-drimenol (1) and (+)-albicanol (2) (Fig. 1) , that showed strong 402 activity against C. albicans. Among these two compounds, 1 showed stronger bioactivity. It acts 403 not only against C. albicans as fungicidal but also against Aspergillus nidulans, FLU resistant 404 strains of C. albicans, C. glabrata, C. krusei, Cryptococcus spp and other dermatophytes, 405
suggesting that 1 is a broad-spectrum antifungal agent (Figs. 2, 3 and Table 2) . At an increased 406 concentration (100 μg/ml), 1 caused rupturing of the fungal cell wall/membrane, e.g. C. albicans 407 ( Fig. 3) and Cryptococcus sp. (data not included). Candida auris is an emerging and multi 408 antifungal resistant strain that causes nosocomial infection and has been reported recently across 409 the world (18). Our bioscreen-based growth curve monitoring assay with 1 showed better activity 410 than clinical antifungal drug FLU (Fig. 4) indicating a potential use of 1 against C. auris and other 411 drug-resistant fungal pathogens. 412
413
Molecule 1 is a natural product presents in liverworts and higher plants (44, 45), and its antifungal 414 mechanism against human pathogenic fungi has not been reported previously. A recent study has 415
shown that 1 has antifungal activity against Botrytis cinerea, a plant fungal pathogen and the 416 mechanisms appear to act by fungal membrane damage and reactive oxygen species (ROS) 417 production (46). 418
419
In order to develop broad-spectrum novel antifungal compounds, we evaluated 1 against various 420 fungi that are pathogenic to humans and determined its mechanisms of action in C. albicans and 421 S. cerevisiae. Based on our yeasts mutant screening data and subsequent spot assay results, we 422 found that 1 acts as a fungicidal compound by affecting cellular activities targeting protein 423 trafficking between Golgi to ER, protein secretion (Sec system) and cell signaling, possibly 424 through cell division related kinase 1, Crk1 (Figs. 7 & 8) . Genetic methods have been used to 425 determine the mechanism of antifungal compounds by drug-induced hypersensitivity assay (22, 426 47). Using similar approaches, we showed that 1-mediated inhibition of C. albicans heterozygous 427 mutants of CDC37, Orf19.759, Orf19.1672 and Orf19.4382, the known or putative targets of Crk1 428 kinase, at sub-MIC concentration. In support of this observation, computational molecular 429 docking of 1 with the crystal structure of a fungal (C. parvum) Crk1 kinase showed interactions of 430 1 with the key residues in the catalytic domain (N-terminal) of Crk1 (Fig. 9) . 431 432 Cinnamodial is a closely related compound belong to the drimane sesquiterpenoid family with 433 potent antifungal activity (48), but its chemical structure (containing dialdehyde groups ; Fig. 1 ) 434 and physiological properties are quite different from 1. For example, the antifungal activity of 435 cinnamodial was shown to abolish by amine compounds (likely due to a coupling reaction from 436 the aldehyde functions of cinnamodial with the amino group of amine compounds) or when 437 cinnamodial was incubated in YPD medium (19, 49) . In contrast, molecule 1's bioactivity was 438 not affected by amines or YPD medium (Fig. 5) . Thus, the antifungal mechanisms of 1 could be 439 different from cinnamodial. Since the synthetic route for 1 and its analogs are well established, 440 improvements of its antifungal properties are possible through medicinal chemistry approaches. 441
In summary, we have synthesized a focused library of drimane sesquiterpenoid compounds and 442 identified 1 as a broad-spectrum fungicidal compound against various human pathogenic fungi 443 including C. albicans, C. auris, Cryp. neoformans, Aspergillus, Blastomyces, Scedosporium, 444 Fusarium, Pneumocystis, and dermatophytes at 8 -64 g/ml. By employing the libraries of bar-445 coded C. albicans and S. cerevisiae genome-wide mutants, the mechanism of action of 1 was 446 determined. Further evaluation of 1 in animal models of fungal diseases would help develop 1 as 447 an antifungal agent. 448
449
MATERIALS AND METHODS 450 451
Synthesis of drimane molecules. (1R,2R,4aS,8aS)-2-Hydroxy-2,5,5,8a-tetramethyl-452 decahydronaphthalene-1-carbaldehyde (4). To a solution of 0.20 g (0.74 mmol) of triol 3 (13) 453 in 10 ml of THF and 2.5 ml of water was added 0.19 g (0.81 mmol) of potassium periodate. The 454 resulting mixture was stirred at 25 o C for 4 hours, diluted with water (50 ml) and extracted three 455 times with ethyl acetate (50 ml each). The combined extract was washed with water and brine, 456 dried (anhydrous Na2SO4), concentrated, and column chromatographed on silica gel using a 457 mixture of hexane and ethyl acetate (20:1) as an eluent to give 0.16 g (91% yield) of compound 4, 458 whose spectral data is in agreement with that reported (13). 459 2R,4aS,8aS)-1-(Hydroxymethyl)-2,5,5,8a- reaction mixture was diluted with 10 ml of aqueous ammonium chloride and extracted with diethyl 488 ether three times (10 ml each). The combined extracts were washed with water (10 ml) and brine 489 (10 ml), dried (anhydrous Na2SO4), concentrated to give 12.5 mg of the mono-silylated product. 490
This crude product was used in the subsequent step without purification. To a solution of the 491 above mono-silylated product and 0.1 ml of pyridine in 0.5 ml of dichloromethane under argon at 492 0 o C, was added 10 l (0.13 mmol) of acetyl chloride. The reaction mixture was stirred at 25 o C for 493 2 h, diluted with aqueous ammonium chloride (10 ml), and extracted three times with diethyl ether 494 (10 ml each). The combined extracts were washed with brine, dried (anhydrous Na2SO4), 495 concentrated to give the crude product, which was used in the following step without purification. 496
The above crude product was dissolved in 1 ml of dried THF (distilled over sodium/benzophenone) 497 and 0.3 ml (0.3 mmol) of tetra-n-butylammonium fluoride (1 M solution in THF) and stirred at 498 25 o C under argon for 1 h. The reaction solution was diluted with 0.1 N ammonium hydroxide (10 499 ml) and extracted with diethyl ether three times (10 ml each). The combined extracts were washed 500 with water (10 ml) and brine (10 ml), dried (anhydrous Na2SO4), concentrated, and column 501 chromatographed on silica gel using a gradient mixture of hexane and diethyl ether to give 4.2 mg 502 (38% overall yield from diol 5) of compound 7. 1S,2R,4aS,8aS)-1-(2,2-Dimethyl-1,3-dioxolan-4-yl) Omaha NE). Briefly, yeast cells or conidia (for filamentous fungi) were suspended in RPMI 1640 536 medium to a final concentration of 10 5 cfu/ml and distributed in 96-well microplate to a total 537 volume of 100 l/well. Drimenol or albicanol was added into the wells and a two-fold serial 538 dilution was made. Duplicates were used for each concentration and wells with or without DMSO 539 served as controls. Plates were incubated without shaking at 37 o C for 24 -48h for yeasts and 30 o C 540 for 4 days for filamentous fungi (Aspergillus sp and Trichophyton sp). The MIC was defined as 541 the lowest compound concentration at which no growth occurred, as determined visually and 542 microscopically (inverted microscope). 543 544
Determination of C. auris growth inhibition by drimenol 545
The effect of drimenol on the growth of C. auris was determined by Bioscreen-C real time growth 546 monitoring system (Oy Growth Curves Ab Ltd, Finland) as described earlier (50). Briefly, 200 µl 547 of RPMI medium containing exponentially growing C. auris yeast cells (each at 0.07 OD600) 548 were added into the honeycomb wells with or without compound (control) and measured their 549 growth rates for 20 hours at 37ºC. Compound treatment was done at two different concentrations 550 for drimenol (50 and 60 µg/ml). The absorbance was measured at 600 nm at 30 min intervals for 551 24 h at 37°C with shaking for 10 s before each reading. Solvent negative control (DMSO) and 552 FLU (60 µg/ml; antifungal drug) positive control were included in the study. The experiments 553 were repeated at least two times with three technical replicates. 554 555
Yeast spot assay 556
Yeast Peptone Dextrose (YPD) agar containing a sub-MIC concentration of drimenol (30 µg/ml) 557 or an equal volume of DMSO was used to spot test the C. albicans heterozygous mutants (GRACE 558 library (25)). Yeast suspensions of various mutants and the wild type C. albicans were used. Five 559 μl of a four-fold serially diluted suspension was spotted on the agar plates and incubated at 30 o C 560 for yeast growth for 24 h, and photographed. Experiments were repeated at least three times and 561 a representative result was shown. 562 563
Genome-wide fitness assay 564
The Saccharomyces yeast deletion collection was comprised of approximately 5,900 individually 565 bar-coded heterozygous diploid strains (HIP [haploinsufficiency profiling]) and ~4,800 566 homozygous diploid strains (HOP [homozygous deletion profiling]). Pools of approximately 567 equal strain abundance were generated by robotically pinning (S and P Robotics, Ontario, Canada) 568 each strain (from frozen stocks) onto YPD agar plates as arrays of 384 strains/plate (21, 51, 52). 569
After 2 days of growth at 30°C, colonies were collected from plates by flooding with YPD, and 570 cells were adjusted to an optical density at 600 nm (OD 600 ) of 2. The fitness of each strain in each 571 experimental pool was assessed as described previously (21). The dose that resulted in 15% 572 growth inhibition in S. cerevisiae BY4743 (the parent strain of the yeast deletion collection) was 573 determined by analyzing dose response over the course of 16 h of growth at 30°C. Screens of the 574 homozygous deletion collection were performed for 5 generations of growth and screens of the 575 heterozygous deletion collection were collected after 20 generations of growth. Cells were 576 processed as described previously (21). Genomic DNA was extracted from each sample and 577 subjected to PCR to amplify the unique bar code identifiers. The abundance of each bar code was 578 determined by quantifying the microarray signal as previously described (21). 579
Candida albicans pooled screens used the tn-transposon collection (23). Growth assays were 580 performed in duplicate and samples were recovered at 20 generations of growth. Genomic DNA 581 extraction, tag amplification, and hybridization were performed as described above. 582 583 
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